CR20120648A - Agentes inductores de apoptosis para el tratamiento del cáncer y de enfermedades inmunes y autoinmunes - Google Patents

Agentes inductores de apoptosis para el tratamiento del cáncer y de enfermedades inmunes y autoinmunes

Info

Publication number
CR20120648A
CR20120648A CR20120648A CR20120648A CR20120648A CR 20120648 A CR20120648 A CR 20120648A CR 20120648 A CR20120648 A CR 20120648A CR 20120648 A CR20120648 A CR 20120648A CR 20120648 A CR20120648 A CR 20120648A
Authority
CR
Costa Rica
Prior art keywords
immune
cancer
treatment
autoimmune diseases
inductive agents
Prior art date
Application number
CR20120648A
Other languages
English (en)
Inventor
Zhi-Fu Tao
Xilu Wang
Andrew J Souers
Nathaniel D Catron
Gerard Sullivan
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45004346&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20120648(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of CR20120648A publication Critical patent/CR20120648A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
    • A01N43/36—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom five-membered rings
    • A01N43/38—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom five-membered rings condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
    • A01N43/40—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
    • A01N43/40—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
    • A01N43/42—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Plant Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Pest Control & Pesticides (AREA)
  • Environmental Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dentistry (AREA)
  • Agronomy & Crop Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Una forma de realización de esta invención, por lo tanto, hace referencia a compuestos o sales terapéuticamente aceptables, que son útiles como inhibidores selectivos de uno o más de un miembro de la familia de proteínas antiapoptóticas, donde los compuestos son de fórmula (I), (II) o (III).
CR20120648A 2010-05-26 2012-12-18 Agentes inductores de apoptosis para el tratamiento del cáncer y de enfermedades inmunes y autoinmunes CR20120648A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34842210P 2010-05-26 2010-05-26

Publications (1)

Publication Number Publication Date
CR20120648A true CR20120648A (es) 2013-04-03

Family

ID=45004346

Family Applications (2)

Application Number Title Priority Date Filing Date
CR20180222A CR20180222A (es) 2010-05-26 2011-05-25 Agentes inductores de apoptosis para el tratamiento del cáncer y de enfermedades inmunes y autoinmunes (divisional 2012-648)
CR20120648A CR20120648A (es) 2010-05-26 2012-12-18 Agentes inductores de apoptosis para el tratamiento del cáncer y de enfermedades inmunes y autoinmunes

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CR20180222A CR20180222A (es) 2010-05-26 2011-05-25 Agentes inductores de apoptosis para el tratamiento del cáncer y de enfermedades inmunes y autoinmunes (divisional 2012-648)

Country Status (39)

Country Link
US (5) US9006247B2 (es)
EP (3) EP3091017B1 (es)
JP (1) JP5782508B2 (es)
KR (2) KR101850679B1 (es)
CN (2) CN102939009B (es)
AR (1) AR081552A1 (es)
AU (1) AU2011258350B2 (es)
BR (1) BR112012029733B1 (es)
CA (1) CA2798765C (es)
CL (1) CL2012003285A1 (es)
CO (1) CO6640275A2 (es)
CR (2) CR20180222A (es)
CY (1) CY1117655T1 (es)
DK (1) DK2575463T3 (es)
DO (3) DOP2012000298A (es)
EC (1) ECSP12012348A (es)
ES (2) ES2666181T3 (es)
GT (1) GT201200315A (es)
HK (1) HK1182593A1 (es)
HR (1) HRP20160714T1 (es)
HU (1) HUE029231T2 (es)
IL (2) IL222831A (es)
ME (1) ME02452B (es)
MX (1) MX337104B (es)
MY (1) MY165427A (es)
NZ (1) NZ603284A (es)
PE (2) PE20130221A1 (es)
PH (2) PH12016501126A1 (es)
PL (1) PL2575463T3 (es)
PT (1) PT2575463T (es)
RS (1) RS54892B1 (es)
RU (1) RU2567857C2 (es)
SG (3) SG10201700112VA (es)
SI (1) SI2575463T1 (es)
TW (1) TWI520960B (es)
UA (1) UA109278C2 (es)
UY (1) UY33408A (es)
WO (1) WO2011150016A1 (es)
ZA (1) ZA201208727B (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009085216A2 (en) 2007-12-20 2009-07-09 Squicor Compositions and methods for detecting or elimninating senescent cells to diagnose or treat disease
US8563735B2 (en) 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US20220315555A1 (en) 2009-05-26 2022-10-06 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
US8546399B2 (en) * 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
CA3152557A1 (en) 2010-10-29 2012-05-03 Abbvie Inc. Solid dispersions containing an apoptosis-inducing agent
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
CA2820618C (en) 2010-11-23 2020-04-21 Steven Elmore Use of sulfonylbenzamide compounds in the treatment of systemic lupus erythematosus, lupus nephritis, or sjogren's syndrome
US20140189897A1 (en) 2011-06-21 2014-07-03 Mayo Foundation For Medical Education And Research Transgenic animals capable of being induced to delete senescent cells
KR20140119023A (ko) 2011-12-13 2014-10-08 버크 인스티튜트 포 리서치 온 에이징 의료 요법을 개선하는 방법
WO2013158664A2 (en) 2012-04-17 2013-10-24 Kythera Biopharmaceuticals, Inc. Use of engineered viruses to specifically kill senescent cells
WO2014028381A1 (en) * 2012-08-13 2014-02-20 Abbvie Inc. Apoptosis-inducing agents
US9901080B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells
US9901081B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse for determining the role of senescent cells in cancer
US9539251B2 (en) 2012-09-07 2017-01-10 Genentech, Inc. Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor
BR122021025053B1 (pt) * 2013-03-13 2022-09-06 Abbvie Inc Processo para a preparação de um agente indutor de apoptose
AR095265A1 (es) 2013-03-13 2015-09-30 Abbvie Inc Procesos para la preparación de un agente inductor de la apoptosis
FR3008979B1 (fr) * 2013-07-23 2015-07-24 Servier Lab Nouveaux derives phosphates, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
NZ723035A (en) 2014-01-28 2022-07-01 Buck Inst Res Aging Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders
WO2015116735A1 (en) 2014-01-28 2015-08-06 Mayo Foundation For Medical Education And Research Methods and combinations for killing senescent cells and for treating senescence-associated diseases and disorders
US10328058B2 (en) 2014-01-28 2019-06-25 Mayo Foundation For Medical Education And Research Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques
US9238652B2 (en) 2014-03-04 2016-01-19 Abbvie Inc. Processes for the preparation of an apoptosis-inducing agent
EP3203840B1 (en) 2014-10-06 2020-08-05 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US10195213B2 (en) 2015-03-13 2019-02-05 Unity Biotechnology, Inc. Chemical entities that kill senescent cells for use in treating age-related disease
WO2017063572A1 (zh) * 2015-10-13 2017-04-20 苏州晶云药物科技有限公司 细胞凋亡诱导剂的新晶型及其制备方法
CN106957315B (zh) * 2016-01-08 2019-08-13 中国人民解放军第二军医大学 N-取代苯磺酰基-氮杂吲哚氧基苯甲酰胺类化合物及其制备药物的用途
AU2017240685B2 (en) 2016-03-31 2021-08-12 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US20170300968A1 (en) * 2016-04-14 2017-10-19 Nb Portals, Llc Method and system for disseminating information over a communication network
RU2744358C2 (ru) 2016-08-05 2021-03-05 Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган N-(фенилсульфонил) бензамиды и родственные соединения в качестве ингибиторов bcl-2
CN109803962B (zh) 2016-09-30 2022-04-29 弗特克斯药品有限公司 囊性纤维化跨膜传导调控蛋白的调节剂、以及药物组合物
WO2018107100A1 (en) 2016-12-09 2018-06-14 Vertex Pharmaceuticals Incorporated Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
US11053239B2 (en) 2017-01-07 2021-07-06 Fochon Pharmaceuticals, Ltd. Compounds as BLC-2-selective apoptosis-inducing agents
WO2018157803A1 (zh) * 2017-02-28 2018-09-07 苏州科睿思制药有限公司 维奈妥拉的晶型及其制备方法
CN110546151B (zh) 2017-04-18 2023-04-28 重庆复创医药研究有限公司 凋亡诱导剂
CN108794358B (zh) * 2017-04-27 2022-08-12 中国人民解放军第二军医大学 取代苯磺酰基类化合物及其制备药物的用途
BR112019025801A2 (pt) 2017-06-08 2020-07-07 Vertex Pharmaceuticals Incorporated métodos de tratamento para fibrose cística
AU2018304168B2 (en) 2017-07-17 2023-05-04 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
KR102606188B1 (ko) 2017-08-02 2023-11-23 버텍스 파마슈티칼스 인코포레이티드 피롤리딘 화합물을 제조하기 위한 공정
CN107501260B (zh) * 2017-08-14 2019-08-13 郑州大学第一附属医院 一种Bcl-2抑制剂venetoclax以及中间体的制备方法
ES2971457T3 (es) 2017-08-23 2024-06-05 Guangzhou Lupeng Pharmaceutical Company Ltd Inhibidores de BCL-2
CN107445958A (zh) * 2017-09-19 2017-12-08 上海泓博智源医药股份有限公司 一种abt‑199中间体的制备方法
AU2018351533B2 (en) 2017-10-19 2023-02-02 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of CFTR modulators
KR20200097293A (ko) 2017-12-08 2020-08-18 버텍스 파마슈티칼스 인코포레이티드 낭포성 섬유증 막횡단 전도 조절자의 조정제의 제조 방법
BR112020014169A2 (pt) 2018-01-10 2020-12-08 Recurium Ip Holdings, Llc Compostos de benzamida
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
US20190336496A1 (en) * 2018-02-16 2019-11-07 Abbvie Inc. Selective bcl-2 inhibitors in combination with an anti-pd-1 or an anti-pd-l1 antibody for the treatment of cancers
US11414439B2 (en) 2018-04-13 2022-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
CA3098348A1 (en) 2018-04-29 2019-11-07 Beigene, Ltd. Bcl-2 inhibitors
KR20210003731A (ko) 2018-07-31 2021-01-12 어센테지 파마 (쑤저우) 컴퍼니 리미티드 Bcl-2 억제제와 MDM2 억제제의 병용 제품 및 질환의 예방 및/또는 치료에 있어서 이의 용도
KR20200139139A (ko) 2018-07-31 2020-12-11 어센테지 파마 (쑤저우) 컴퍼니 리미티드 리툭시맙 및/또는 벤다무스틴과 병용된 Bcl-2 억제제 또는 CHOP와 병용된 Bcl-2 억제제의 시너지적 항종양 효과
CN114522167A (zh) 2018-07-31 2022-05-24 苏州亚盛药业有限公司 Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途
US11491167B2 (en) 2018-07-31 2022-11-08 Ascentage Pharma (Suzhou) Co., Ltd. Combination product of Bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases
US11903950B2 (en) 2018-08-22 2024-02-20 Newave Pharmaceutical Inc. BCL-2 inhibitors
CN112661751B (zh) * 2019-10-16 2024-06-14 南京天印健华医药科技有限公司 作为bcl-2抑制剂的杂环化合物
WO2021110102A1 (en) * 2019-12-02 2021-06-10 Beigene, Ltd. Methods of cancer treatment using bcl-2 inhibitor
WO2021231486A1 (en) * 2020-05-13 2021-11-18 Unity Biotechnology, Inc. Cancer treatment by senescence induction followed by a senolytic
CN114736203A (zh) * 2021-01-07 2022-07-12 南京天印健华医药科技有限公司 作为bcl-2抑制剂的杂环化合物
EP4353722A1 (en) * 2021-06-04 2024-04-17 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Phosphate of trifluoromethyl-substituted sulfonamide compound

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY115155A (en) 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
US6277985B1 (en) 1995-09-15 2001-08-21 Pharmacia & Upjohn Company Aminoaryl oxazolidinone N-oxides
US20030220234A1 (en) 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
DE19830430A1 (de) * 1998-07-08 2000-01-13 Hoechst Marion Roussel De Gmbh Schwefelsubstituierte Sulfonylamino-carbonsäure-N-arylamide, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
GB9918037D0 (en) 1999-07-30 1999-09-29 Biochemie Gmbh Organic compounds
UY26942A1 (es) * 2000-09-20 2002-04-26 Abbott Lab N-acilsulfonamidas promotoras de la apoptosis
US6720338B2 (en) 2000-09-20 2004-04-13 Abbott Laboratories N-acylsulfonamide apoptosis promoters
JP4336678B2 (ja) 2003-09-04 2009-09-30 株式会社日立超エル・エス・アイ・システムズ 半導体装置
US7973161B2 (en) 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
US8614318B2 (en) * 2003-11-13 2013-12-24 Abbvie Inc. Apoptosis promoters
WO2005049593A2 (en) 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
WO2005099353A2 (en) 2004-04-19 2005-10-27 Symed Labs Limited A novel process for the preparation of linezolid and related compounds
ATE429423T1 (de) 2004-07-20 2009-05-15 Symed Labs Ltd Neue zwischenprodukte für linezolid und verwandte verbindungen
US7511013B2 (en) 2004-09-29 2009-03-31 Amr Technology, Inc. Cyclosporin analogues and their pharmaceutical uses
WO2007040650A2 (en) 2005-05-12 2007-04-12 Abbott Laboratories Apoptosis promoters
TW200716636A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
US7514068B2 (en) 2005-09-14 2009-04-07 Concert Pharmaceuticals Inc. Biphenyl-pyrazolecarboxamide compounds
CN101534904B (zh) 2006-09-05 2013-11-06 Abbvie公司 治疗血小板过量的bcl抑制剂
US8796267B2 (en) 2006-10-23 2014-08-05 Concert Pharmaceuticals, Inc. Oxazolidinone derivatives and methods of use
US20080182845A1 (en) 2006-11-16 2008-07-31 Abbott Laboratories Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection
RU2460725C2 (ru) 2007-02-15 2012-09-10 Ф. Хоффманн-Ля Рош Аг Новые 2-аминооксазолины в качестве лигандов taar1
US8536157B2 (en) 2007-04-13 2013-09-17 The University Of Melbourne Non-steroidal compounds
CA2686545C (en) 2007-04-19 2010-11-02 Concert Pharmaceuticals Inc. Deuterated morpholinyl compounds
US7531685B2 (en) 2007-06-01 2009-05-12 Protia, Llc Deuterium-enriched oxybutynin
US20090131485A1 (en) 2007-09-10 2009-05-21 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
US20090118238A1 (en) 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
US20090082471A1 (en) 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched fingolimod
US20090088416A1 (en) 2007-09-26 2009-04-02 Protia, Llc Deuterium-enriched lapaquistat
US20090137457A1 (en) 2007-10-02 2009-05-28 Concert Pharmaceuticals, Inc. Pyrimidinedione derivatives
WO2009051782A1 (en) 2007-10-18 2009-04-23 Concert Pharmaceuticals Inc. Deuterated etravirine
US20090105338A1 (en) 2007-10-18 2009-04-23 Protia, Llc Deuterium-enriched gabexate mesylate
US20090131363A1 (en) 2007-10-26 2009-05-21 Harbeson Scott L Deuterated darunavir
NZ601350A (en) 2007-11-16 2013-08-30 Abbvie Inc Method of treating arthritis
UA108193C2 (uk) * 2008-12-04 2015-04-10 Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
US20100160322A1 (en) * 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
EP2376480B1 (en) * 2008-12-05 2016-06-01 AbbVie Inc. Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US8563735B2 (en) 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
MX2011007681A (es) * 2009-01-19 2011-08-08 Abbott Lab Agentes inducidores de apoptosis para el tratamiento del cancer y enfermedades inmunes y autoinmunes.
US8546399B2 (en) * 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
KR101920202B1 (ko) * 2009-05-26 2018-11-21 애브비 아일랜드 언리미티드 컴퍼니 암，면역 질환 및 자가면역 질환의 치료를 위한 아폽토시스-유도제

Also Published As

Publication number Publication date
ES2574855T3 (es) 2016-06-22
PH12018501264A1 (en) 2019-07-01
EP2575463A1 (en) 2013-04-10
CO6640275A2 (es) 2013-03-22
EP3312178A1 (en) 2018-04-25
DOP2012000298A (es) 2018-04-30
CA2798765C (en) 2018-10-23
JP2013526612A (ja) 2013-06-24
NZ603284A (en) 2015-01-30
AU2011258350A1 (en) 2012-11-22
DOP2016000100A (es) 2016-05-31
AU2011258350B2 (en) 2015-04-09
CA2798765A1 (en) 2011-12-01
RU2567857C2 (ru) 2015-11-10
SG10201700112VA (en) 2017-03-30
MY165427A (en) 2018-03-22
US20170096424A1 (en) 2017-04-06
PE20170465A1 (es) 2017-05-18
CN104961771A (zh) 2015-10-07
GT201200315A (es) 2014-07-11
CN102939009B (zh) 2015-03-25
CN102939009A (zh) 2013-02-20
CR20180222A (es) 2018-06-05
TW201141862A (en) 2011-12-01
US20190315737A1 (en) 2019-10-17
US9006247B2 (en) 2015-04-14
KR101850679B1 (ko) 2018-04-20
DOP2017000186A (es) 2017-09-15
BR112012029733A2 (pt) 2017-06-13
PH12016501126B1 (en) 2017-06-14
IL233832B (en) 2018-05-31
ES2666181T3 (es) 2018-05-03
HUE029231T2 (en) 2017-02-28
RS54892B1 (sr) 2016-10-31
PE20130221A1 (es) 2013-04-04
SI2575463T1 (sl) 2016-11-30
ECSP12012348A (es) 2013-04-30
SG185447A1 (en) 2012-12-28
US20120028925A1 (en) 2012-02-02
PL2575463T3 (pl) 2016-10-31
IL233832A0 (en) 2014-09-30
MX337104B (es) 2016-02-09
WO2011150016A1 (en) 2011-12-01
US20200277291A1 (en) 2020-09-03
ME02452B (me) 2016-09-20
PT2575463T (pt) 2016-07-13
US9403822B2 (en) 2016-08-02
IL222831A (en) 2014-08-31
EP2575463B1 (en) 2016-03-30
ZA201208727B (en) 2013-07-31
CN104961771B (zh) 2018-02-02
KR20130086954A (ko) 2013-08-05
UA109278C2 (uk) 2015-08-10
KR101800167B1 (ko) 2017-11-22
CL2012003285A1 (es) 2013-10-04
KR20170083164A (ko) 2017-07-17
UY33408A (es) 2011-12-30
IL222831A0 (en) 2012-12-31
JP5782508B2 (ja) 2015-09-24
CY1117655T1 (el) 2017-05-17
EP3091017B1 (en) 2018-01-17
HK1182593A1 (zh) 2013-12-06
EP3091017A1 (en) 2016-11-09
AR081552A1 (es) 2012-10-03
BR112012029733B1 (pt) 2020-12-01
HRP20160714T1 (hr) 2016-07-15
TWI520960B (zh) 2016-02-11
RU2012156940A (ru) 2014-07-10
US20150246914A1 (en) 2015-09-03
SG10201700115RA (en) 2017-02-27
DK2575463T3 (en) 2016-07-25
EP2575463A4 (en) 2013-11-27
MX2012013704A (es) 2013-03-21
PH12016501126A1 (en) 2017-06-14

Similar Documents

Publication Publication Date Title
CR20120648A (es) Agentes inductores de apoptosis para el tratamiento del cáncer y de enfermedades inmunes y autoinmunes
UY37825A (es) Agentes inductores de la apoptosis para el tratamiento del cáncer y de enfermedades inmunes y autoinmunes
ECSP17073191A (es) Compuestos heterocíclicos como inhibidores de lsd1
ECSP16073190A (es) Ciclopropilaminas como inhibidores de lsd1
CL2018002759A1 (es) Compuestos de pirrolotriazina como inhibidores de tam.
CL2019002304A1 (es) Compuestos para el tratamiento del cáncer.
CL2018001591A1 (es) Compuestos útiles como inhibidores de cinasa.-
CL2019002461A1 (es) Arn terapéutico.
CL2018003123A1 (es) Terapia de combinación para el tratamiento del cáncer
GT201400133A (es) Inhibidores de bromodominios
CL2019000844A1 (es) Compuesto de piridina.
CR20120659A (es) Derivados de piperidinona como inhibidores mdm2 para el tratamiento de cáncer
ECSP16073171A (es) Ciclopropilaminas como inhibidores de lsd1
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
DOP2015000157A (es) Lactamas fusionadas de arilo y heteroarilo
CL2013002552A1 (es) Uso de una combinación de un compuesto derivado de 3-fenil-2-[1-(9h-purin-6-ilamino)alquil]quinazolin-4-ona y uno o más agentes terapéuticos seleccionados entre bendamustina, rituximab, lenalidomida y ofatumumab, para el tratamiento del cáncer.
CO6571908A2 (es) Agentes inductores de apoptosis para el tratamiento de cancer y enfermedaded inmunes y autoinmunes
CL2015002571A1 (es) Composiciones y métodos para le diagnostico y tratamiento del cáncer hepático.
GT201200172A (es) Derivados de sulfonamida como agentes inductores de apoptosis con selectividad por bcl-2 para el tratamiento de cáncer y enfermedades inmunes
AR091837A1 (es) Compuestos para inmunoterapia dirigida
GT201200230A (es) Inhibidores del virus de la hepatitis c
UY34165A (es) ?compuestos aldh-2 mitocondriales humanos para el tratamiento de la adicción?.
NI201500042A (es) Antiandrógenos para el tratamiento del cáncer de próstata resistente a la castración no metastásico
GT201200004A (es) Imidazoles fusionados y composiciones que los contienen para el tratamiento de enfermedades parasitarias, como por ejemplo malaria
CR20140400A (es) Terapia combinada para el tratamiento del cancer de ovario